Insider · CIK 0001678984

Schilke Tobin

Reports to the SEC for 3 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001678984

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Chief Financial & Infra. Ofcr.	DDisposition to Issuer	−7,956 sh	$85.00	−$676K	71,471
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Chief Financial & Infra. Ofcr.	DDisposition to Issuer	−71.5K sh	$85.00	−$6.08M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial & Infra. Ofcr.	DDisposition to Issuer	−80K sh	$51.25	−$4.1M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial & Infra. Ofcr.	DDisposition to Issuer	−50K sh	$41.21	−$2.06M	0
2026-08-20	CRNXCrinetics Pharmaceuticals, Inc.A Award	Chief Financial & Infra. Ofcr.	AAward	+471 sh	—	—	79,427
2026-03-03	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Chief Financial & Infra. Ofcr.	SSale	−6,713 sh	$39.67	−$266K	78,121
2026-02-23	CRNXCrinetics Pharmaceuticals, Inc.A Award	Chief Financial & Infra. Ofcr.	AAward	+32K sh	—	—	84,834
2026-02-23	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Financial & Infra. Ofcr.	AAward	+50K sh	—	—	50,000
2025-03-10	CRNXCrinetics Pharmaceuticals, Inc.A Award	Chief Financial & Infra. Ofcr.	AAward	+52K sh	—	—	52,000
2025-03-10	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Financial & Infra. Ofcr.	AAward	+80K sh	—	—	80,000
2025-02-06	Revance Therapeutics, Inc.D Disposition to Issuer	CFO	DDisposition to Issuer	−104K sh	—	—	0
2025-02-06	Revance Therapeutics, Inc.A Award	CFO	AAward	+20.9K sh	—	—	20,883
2025-02-06	Revance Therapeutics, Inc.D Disposition to Issuer	CFO	DDisposition to Issuer	−20.9K sh	—	—	0
2025-02-04	Revance Therapeutics, Inc.U Disposition from Tender	CFO	UDisposition from Tender	−98K sh	$3.65	−$358K	103,555
2025-02-03	Revance Therapeutics, Inc.A Award	CFO	AAward	+6,888 sh	—	—	201,554
2024-12-31	Revance Therapeutics, Inc.A Award	CFO	AAward	+1,000 sh	$2.18	+$2,184.5	194,666
2024-06-30	Revance Therapeutics, Inc.A Award	CFO	AAward	+1,000 sh	$2.18	+$2,184.5	193,666
2024-03-18	Revance Therapeutics, Inc.S Sale	CFO	SSale	−9,361 sh	$5.04	−$47.2K	192,666
2024-03-15	Revance Therapeutics, Inc.F Tax Payment	CFO	FTax Payment	−3,822 sh	$5.30	−$20.3K	202,027
2024-02-29	Revance Therapeutics, Inc.A Award	CFO	AAward	+17.4K sh	—	—	205,849
2024-01-31	Revance Therapeutics, Inc.A Award	CFO	AAward	+96.7K sh	—	—	188,402
2024-01-31	Revance Therapeutics, Inc.Performance Stock UnitsA Award	CFO	AAward	+145K sh	—	—	145,001
2023-12-31	Revance Therapeutics, Inc.A Award	CFO	AAward	+434 sh	$7.47	+$3,241.98	91,735
2023-08-11	Revance Therapeutics, Inc.A Award	CFO	AAward	+22.6K sh	—	—	102,516
2023-08-11	Revance Therapeutics, Inc.F Tax Payment	CFO	FTax Payment	−11.2K sh	$18.91	−$212K	91,301
2023-07-03	Revance Therapeutics, Inc.S Sale	CFO	SSale	−1,701 sh	$25.04	−$42.6K	79,896
2023-06-30	Revance Therapeutics, Inc.A Award	CFO	AAward	+769 sh	$15.61	+$12K	81,597
2023-06-02	Revance Therapeutics, Inc.S Sale	CFO	SSale	−500 sh	$31.00	−$15.5K	80,828
2023-06-01	Revance Therapeutics, Inc.S Sale	CFO	SSale	−2,701 sh	$30.57	−$82.6K	81,328
2023-05-15	Revance Therapeutics, Inc.S Sale	CFO	SSale	−21.4K sh	$34.55	−$739K	84,029
2023-05-01	Revance Therapeutics, Inc.S Sale	CFO	SSale	−3,201 sh	$31.70	−$101K	63,081
2023-04-03	Revance Therapeutics, Inc.S Sale	CFO	SSale	−3,201 sh	$32.15	−$103K	66,282
2023-03-15	Revance Therapeutics, Inc.F Tax Payment	CFO	FTax Payment	−3,739 sh	$30.65	−$115K	69,483
2023-03-09	Revance Therapeutics, Inc.S Sale	CFO	SSale	−18.5K sh	$31.59	−$585K	73,222
2023-03-01	Revance Therapeutics, Inc.S Sale	CFO	SSale	−3,201 sh	$33.50	−$107K	49,390
2023-02-15	Revance Therapeutics, Inc.F Tax Payment	CFO	FTax Payment	−2,085 sh	$33.21	−$69.2K	52,591
2023-02-01	Revance Therapeutics, Inc.S Sale	CFO	SSale	−3,201 sh	$34.60	−$111K	54,676
2023-01-31	Revance Therapeutics, Inc.Employee Stock Option (Right to Buy)A Award	CFO	AAward	+50.4K sh	—	—	50,435
2023-01-20	Revance Therapeutics, Inc.S Sale	CFO	SSale	−1,000 sh	$31.00	−$31K	57,877
2023-01-09	Revance Therapeutics, Inc.S Sale	CFO	SSale	−1,701 sh	$25.00	−$42.5K	60,877
2023-01-09	Revance Therapeutics, Inc.S Sale	CFO	SSale	−1,000 sh	$28.00	−$28K	59,877
2023-01-09	Revance Therapeutics, Inc.S Sale	CFO	SSale	−1,000 sh	$30.00	−$30K	58,877
2022-12-31	Revance Therapeutics, Inc.A Award	CFO	AAward	+645 sh	$12.18	+$7,856.423	62,578
2022-12-15	Revance Therapeutics, Inc.F Tax Payment	CFO	FTax Payment	−1,557 sh	$21.50	−$33.5K	61,933
2022-09-22	Revance Therapeutics, Inc.A Award	CFO	AAward	+42.3K sh	—	—	91,739
2022-06-30	Revance Therapeutics, Inc.A Award	CFO	AAward	+965 sh	$11.75	+$11.3K	63,490
2022-03-15	Revance Therapeutics, Inc.F Tax Payment	CFO	FTax Payment	−2,607 sh	$15.79	−$41.2K	62,525
2022-02-15	Revance Therapeutics, Inc.F Tax Payment	CFO	FTax Payment	−2,241 sh	$13.35	−$29.9K	65,815
2022-02-15	Revance Therapeutics, Inc.F Tax Payment	CFO	FTax Payment	−683 sh	$13.35	−$9,118.05	65,132
2022-02-02	Revance Therapeutics, Inc.Employee Stock Option (Right to Buy)A Award	CFO	AAward	+68.1K sh	—	—	68,093

Recent filings

Accepted (ET)
Sep 14
Schilke Tobin0001628280-26-059883
SEC(opens sec.gov)
Aug 244
Schilke Tobin0001628280-26-058664
SEC(opens sec.gov)
Mar 44
Schilke Tobin0001628280-26-014772
SEC(opens sec.gov)
Feb 254
Schilke Tobin0001628280-26-011728
SEC(opens sec.gov)
Mar 114
Schilke Tobin0000950170-25-037200
SEC(opens sec.gov)
Feb 64
Schilke Tobin0000950170-25-015362
SEC(opens sec.gov)
Feb 54
Schilke Tobin0000950170-25-014824
SEC(opens sec.gov)
Jan 34
Schilke Tobin0001479290-25-000005
SEC(opens sec.gov)
Jul 24
Schilke Tobin0001479290-24-000103
SEC(opens sec.gov)
Mar 194
Schilke Tobin0001479290-24-000066
SEC(opens sec.gov)
Mar 44
Schilke Tobin0001479290-24-000051
SEC(opens sec.gov)

Companies

Address

C/O CRINETICS PHARMACEUTICALS, INC. 6055 LUSK BOULEVARD

SAN DIEGO, CA, 92121